Longeveron (LGVN) EBT Margin (2020 - 2026)
Longeveron's (LGVN) quarterly EBT Margin came in at 1393.22% in Q1 2026, up 31177.0% year-on-year from N/an in Q1 2025, and up 18.66% quarter-over-quarter from 1712.88% in Q4 2025.
Longeveron (LGVN) EBT Margin (2020 - 2026) Analysis & Trends
Longeveron's EBT Margin history runs 7 years deep, the most recent figure standing at 1393.22% for Q1 2026.
- On a quarterly basis, EBT Margin rose 31177.0% year-over-year to 1393.22% in Q1 2026; TTM through Mar 2026 was 2251.97%, a 134582.0% decrease from a year earlier, with the FY2025 full-year figure at 2030.03%, down 58621.0% from the prior year.
- EBT Margin grew to 1393.22% in Q1 2026 per LGVN's latest filing, from 1712.88% in the prior quarter.
- Across five years, EBT Margin topped out at 630.4% in Q3 2024 and bottomed at 15310.39% in Q1 2023.
- The 5-year median for EBT Margin is 1712.88% (2025), against an average of 3462.08%.
- Across the five-year window, EBT Margin sank 2580570 bps in 2022 and soared 1452317 bps in 2024, its largest moves.
- Year by year, EBT Margin stood at 4321.49% in 2022, then sank by 101 bps to 8684.13% in 2023, then surged by 90 bps to 869.98% in 2024, then tumbled by 97 bps to 1712.88% in 2025, then advanced by 19 bps to 1393.22% in 2026.
- Per Business Quant, the three latest LGVN EBT Margin figures stand at 1393.22% (Q1 2026), 1712.88% (Q4 2025), and 6407.3% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | -1,393.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,393.22% |
| Dec 31, 2025 | -1,712.88% |
| Sep 30, 2025 | -6,407.30% |
| Jun 30, 2025 | -2,154.75% |
| Mar 31, 2025 | -1,704.99% |
| Dec 31, 2024 | -869.98% |
| Sep 30, 2024 | -630.40% |
| Jun 30, 2024 | -757.91% |
| Mar 31, 2024 | -787.23% |
| Dec 31, 2023 | -8,684.13% |
| Sep 30, 2023 | -3,590.00% |
| Jun 30, 2023 | -2,741.94% |
| Mar 31, 2023 | -15,310.39% |
| Dec 31, 2022 | -4,321.49% |
| Sep 30, 2022 | -5,411.00% |
| Jun 30, 2022 | -1,056.44% |
| Mar 31, 2022 | -1,321.29% |
| Dec 31, 2021 | 21,484.21% |
| Sep 30, 2021 | -9,872.84% |
| Jun 30, 2021 | -4,102.66% |